Ozempic’s Unexpected Benefits Included Reduced Alcohol and Vaping Desires! 

Ozempic's Unexpected Benefits Included Reduced Alcohol and Vaping Desires. Credit | Getty Images
Ozempic's Unexpected Benefits Included Reduced Alcohol and Vaping Desires. Credit | Getty Images

United States: In this shocking case, it was shown, a patient who was taking Ozempic (a drug used for type 2 diabetes and weight loss) over a long period of time and it helped minimize her desire for the consumption and intoxication of alcohol. 

She mentioned, “It’s like someone’s just come along and switched the light on, and you can see the room for what it is,” and, “And all of these vapes and cigarettes that you’ve had over the years, they don’t look attractive anymore. It’s very, very strange. Very strange,” CNN Health reported. 

Further Investigation by Novo Nordisk 

Many similar to that response described by the other veterans who used agents from this class (est. 15 Million in number), which encompass the GLP-1 receptor agonists, have also encountered this phenomenon. 

In this regard, Novo Nordisk manufacturing the drug has stated that there is an ongoing probe that uncovers the commercially marked weight loss medication. 

Ozempic's Unexpected Benefits Included Reduced Alcohol and Vaping Desires. Credit | Getty Images
Ozempic’s Unexpected Benefits Included Reduced Alcohol and Vaping Desires. Credit | Getty Images

The company will examine how semaglutide, the active ingredient in Ozempic and other medications, affects alcohol consumption. This investigation is scheduled to be completed this month. However, it’s important to note that reducing alcohol consumption is not the primary purpose of this trial. 

New Trial by Novo Nordisk 

Novo Nordisk, a Danish pharmaceutical company, confirmed that the primary objective of the new trial is to assess whether these medications can improve liver health

Novo Nordisk stated, “Secondary endpoints include safety and tolerability and changes in alcohol consumption,” and “There is a significant unmet medical need in alcohol-related liver disease, and the first line of treatment for the condition is lifestyle intervention to refrain from drinking alcohol.” 

According to a report by Bloomberg News, the trial aims to recruit 240 participants and is scheduled to begin on May 20, according to a government database. 

The spokesperson from Novo Nordisk said, “Even though not all patients in the trial will have alcohol use disorder, it is natural to include alcohol consumption as a secondary endpoint,” while noting that the trial is a part of the company’s major plan of addressing liver diseases. 

Experts’ Perspectives 

According to Christian Hendershot, an assistant professor in the Department of Psychiatry and Bowles Center of Alcohol Studies at the University of North Carolina at Chapel Hill, “Those of us doing work in this area see this as a step in the right direction,” and “Additional treatment options for this group are really needed,” as CNN Health reported. 

Lars Fruergaard Jorgensen, Novo Nordisk’s CEO, said, “We know that one of the benefits in obesity is that it addresses this craving, the desire to snack and eat,” and, “That function in the brain, in this craving center, is perhaps also what is benefitting some of the other addictions.”